Switzerland-based Nycomed has posted a 0.5% rise in turnover for the second quarter to 786.9 million euros, a healthy result given the effects of generic competition to its gastrointestinal drug pantoprazole.

Nycomed’s adjusted earnings before interest, taxes, depreciation and amortisation reached 254.8 million euros, up 2.5%. Pantoprazole sales slipped 1.4% to 316.2 million euros, given the loss of its substance patent in the major European markets in May (where sales fell 11.7%), while turnover in Canada sank due to generic competition.

However, this was offset by growth in US sales and positive development in Asia-Pacific, Africa, Middle East and Latin America. Also an over-the-counter formulatrion of pantoprazole OTC received marketing authorisation for Europe in June and was launched in Germany at the beginning of July, “with encouraging initial sales data”. Launches of the product in further European markets will take place in the coming months.

Nycomed’s specialty products were up 4.4% to 126.4 million euros, driven by strong performances from Preotact (parathyroid hormone [PTH 1-84]) for the treatment of osteoporosis and the haemostatic agent TachoSil (ibrinogen/thrombin).

Chief executive Hakan Bjorklund noted that “the current global downturn continues to have an impact on our business, particularly on the sales of OTC products in the emerging markets”. He added that “the trading environment will remain challenging” for the full year, but Nycomed’s strategy of in-licensing “promising new products and expanding our focus on emerging markets such as the Asia-Pacific region positions us well for continued success in 2009 and beyond”.

Earlier this month, Nycomed signed up Forest Laboratories to sell its chronic obstructive pulmonary disease drug Daxas (roflumilast) in the USA and the Zurich-headquartered firm is reportedly planning a bid to acquire Solvay’s pharmaceutical division.